Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis

Green, Heather D.; Bright-Thomas, R.J.; Mutton, Ken; Guiver, Malcolm; Jones, Andrew M.

doi:10.1016/j.jinf.2016.05.001

Cited by 15 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumocystis colonization in this population is highly variable but is estimated to occur in 7.4-32.8% of CF patients [4,57,58], significantly higher than in healthy populations, and may be dependent upon geographical location [59,60]. Despite the paucity of Pneumocystis colonization within CF patients, a prospective study found that the rate of colonization was five times higher in CF patients undergoing acute respiratory attacks (9.2%) than in stable CF patients (2%), implicating colonization incidence with the severity of disease [61]. Moreover, it has been suggested that these patients may serve as a reservoir for human transmission that put other susceptible populations at risk during outpatient treatment.…”

Section: Cystic Fibrosismentioning

confidence: 99%

Pneumocystis as a Co-Factor in Pulmonary Diseases

Rabacal¹,

Rayens²,

Norris³

2018

obm genet

View full text Add to dashboard Cite

Pneumocystis causes life-threatening pneumonia in immunocompromised populations. More recently it has been implicated as a co-factor in a number of chronic lung diseases including chronic obstructive pulmonary disease (COPD), severe asthma, and cystic fibrosis (CF). In this review, we will examine the current literature regarding Pneumocystis and lung diseases in the HIV-infected patients and non-HIV immunocompromised populations, and the barriers to prophylaxis and treatment in these patients. Trimethoprim sulfamethoxazole (TMP-SMX) is an effective therapeutic against Pneumocystis but this approach remains problematic due to drug interactions, treatment-limiting adverse events, and breakthrough Pneumocystis pneumonia (PCP) despite prophylaxis. This review summarizes the shortcomings of current prophylaxis and treatment strategies, and the advances that have been made toward the development of novel diagnostics and therapeutics, with a focus on vaccine development.

show abstract

Section: Cystic Fibrosismentioning

confidence: 99%

Pneumocystis as a Co-Factor in Pulmonary Diseases

Rabacal¹,

Rayens²,

Norris³

2018

obm genet

View full text Add to dashboard Cite

show abstract

“…The frequencies of P. jirovecii colonization in patients enrolled in these seven studies differ significantly. Specifically, the frequency observed in Brittany, Western France, differed from that was observed in Seville, Porto Alegre, and other French regions, whereas it did not differ from that observed in Munich and in Manchester (Sing et al, 2001 ; Respaldiza et al, 2005 ; Le Gal et al, 2010 ; Hernandez-Hernandez et al, 2012 ; Pederiva et al, 2012 ; Green et al, 2016 ; Nevez et al, 2018 ) ( Table 1 ).…”

Section: Pulmonary Colonization With P Jirovecii mentioning

confidence: 76%

“…In the French multicenter study (Hernandez-Hernandez et al, 2012 ), the presence of P. aeruginosa mucoid-strains showed a negative association with P. jirovecii presence. In the Manchester study, no difference of microbiota in CF patients with exacerbation and with or without P. jirovecii colonization was observed (Green et al, 2016 ). These studies were based on the results of microbial cultures combined with those of P. jirovecii DNA amplification since this fungus is uncultivable.…”

Section: Pulmonary Colonization With P Jirovecii mentioning

confidence: 99%

“…In Manchester, United Kingdom, sputum specimens from 111 patients were prospectively assayed using a qPCR amplifying the mtLSUrRNA gene (Green et al, 2016 ). The fungus was detected in nine patients (8.1%) with a higher frequency in specimens from patients presenting with pulmonary exacerbation than in those from patients without exacerbation (9.2 vs. 2%, p = 0.03).…”

Section: Pulmonary Colonization With P Jirovecii mentioning

confidence: 99%

“…The first data on pulmonary colonization with P. jirovecii in CF patients were obtained in Munich, Germany (Sing et al, 2001 ). Further studies provided additional data in this field (Respaldiza et al, 2005 ; Le Gal et al, 2010 ; Hernandez-Hernandez et al, 2012 ; Pederiva et al, 2012 ; Green et al, 2016 ; Nevez et al, 2018 ). Moreover, PCP can also occur in CF patients (Royce and Blumberg, 2000 ; Quattrucci et al, 2005 ; Solé et al, 2006 ; Kaur et al, 2016 ; Wojarski et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pneumocystis jirovecii in Patients With Cystic Fibrosis: A Review

Bonnet

Gal

Calderón

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Pneumocystis pneumonia (PCP) remains the most frequent AIDS-defining illness in developed countries. This infection also occurs in non-AIDS immunosuppressed patients, e.g., those who have undergone an organ transplantation. Moreover, mild Pneumocystis jirovecii infections related to low pulmonary fungal burden, frequently designated as pulmonary colonization, occurs in patients with chronic pulmonary diseases, e.g., cystic fibrosis (CF). Indeed, this autosomal recessive disorder alters mucociliary clearance leading to bacterial and fungal colonization of the airways. This mini-review compiles and discusses available information on P. jirovecii and CF. It highlights significant differences in the prevalence of P. jirovecii pulmonary colonization in European and Brazilian CF patients. It also describes the microbiota associated with P. jirovecii in CF patients colonized by P. jirovecii. Furthermore, we have described P. jirovecii genomic diversity in colonized CF patients. In addition of pulmonary colonization, it appears that PCP can occur in CF patients specifically after lung transplantation, thus requiring preventive strategies. In other respects, Pneumocystis primary infection is a worldwide phenomenon occurring in non-immunosuppressed infants within their first months. The primary infection is mostly asymptomatic but it can also present as a benign self-limiting infection. It probably occurs in the same manner in CF infants. Nonetheless, two cases of severe Pneumocystis primary infection mimicking PCP in CF infants have been reported, the genetic disease appearing in these circumstances as a risk factor of PCP while the host-pathogen interaction in older children and adults with pulmonary colonization remains to be clarified.

show abstract

Clinical Syndromes: Pneumocystis

Rath

2018

Clinically Relevant Mycoses

View full text Add to dashboard Cite

Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis

Cited by 15 publications

References 18 publications

Pneumocystis as a Co-Factor in Pulmonary Diseases

Pneumocystis as a Co-Factor in Pulmonary Diseases

Pneumocystis jirovecii in Patients With Cystic Fibrosis: A Review

Clinical Syndromes: Pneumocystis

Contact Info

Product

Resources

About